 The bio pharmaceutical industry is composed of two parts: the biotechnology industry and the pharmaceutical industry. According to the category of the bio pharmaceutical industry, China defines the bio pharmaceutical industry as an industry that combines modern biotechnology with the research, development and production of new drugs, as well as the diagnosis, prevention and treatment of various diseases.
The biomedical industry is divided into three fields, namely, pharmaceutical industry, medical device and medical bioengineering material industry and medical diagnostic reagent industry. It includes not only gene recombinant drugs, chemical pharmaceuticals, botanicals, traditional Chinese medicine and other biological products, but also medical equipment, medical diagnostic equipment, medical treatment equipment, medical bioengineering materials, immune reagents, etc.
Development Status of Biomedical Industry Output value of global biomedical industry From the perspective of the distribution of the world's bio pharmaceutical industry, North America, Europe and Japan are the three regions with highly developed bio pharmaceutical industry in the world; From the perspective of industrial layout, although the distribution of global biopharmaceutical enterprises is highly concentrated, the United States, Western Europe, Japan and other developed countries are still the main countries for the development of biotechnology pharmaceutical products. In 2020, the output value of the global biomedical industry will be about US $2.9 trillion, an increase of 9% over 2019. Looking at the world, the scale of the biomedical market is growing rapidly and steadily, and will maintain a growth rate of 5% - 7% in the next five years. It is estimated that by 2025, the output value of the global biomedical industry will reach $4 trillion. 
Global biomedical industry output value (trillion dollars) and growth rate
Output value of China's bio pharmaceutical industry As the world's second largest economy, China's biomedical market has developed rapidly and is gradually favored by multinational biomedical enterprises. From the perspective of regional development, China's bio pharmaceutical industry has formed three comprehensive bio pharmaceutical industry bases, namely, the growth triangle, the Bohai Rim and the Pearl River Delta. In addition, the Northeast, Henan, Hunan and Hubei in the central region, and Sichuan and Chongqing in the western region have also formed an industrial pattern of rapid development of biomedicine. In 2020, the output value of China's bio pharmaceutical industry will be about 3.6 trillion yuan, an increase of 9% over 2019. It is estimated that in the next five years, China's biomedical market will maintain a growth rate of 8% - 9%, and by 2025, the output value of China's biomedical industry will reach 5.4 trillion yuan. 
Output value and growth rate of China's bio pharmaceutical industry (trillion yuan)
Development Direction of Biomedical Contract Industry our country Development Direction of Biomedical Contract Industry It mainly includes four categories: biological therapeutic drugs (such as tumor treatment), biological preventive drugs (such as vaccines), biological diagnostic drugs (such as genetic diagnostic reagents, other biological agents (blood products, etc.), and it is defined that biological drugs do not include small molecule chemicals and traditional Chinese medicine. Biomedical upstream It includes the production of APIs and the R&D of biomedicine, of which R&D is a very important link. The birth of biomedicine is inseparable from R&D and experiment. In addition, the upstream should also include talent training, technical exchanges, etc. middle reaches It mainly involves the production and sales of biomedicine. In addition, it also includes the production and sales of biomedicine equipment. Biomedical downstream It is the end of its industrial chain and the end of the circulation of biomedicine. At this stage, the terminal channels of biomedicine mainly include hospitals, clinics, pharmacies, etc., and e-commerce channels are the future development trend. Prospects for the development of biomedical industry 1. Policy support - The development of the biomedical industry in the future will be supported by national policies. In recent years, the Chinese government has continuously increased its investment and support in the biomedical industry, which has rapidly improved the speed and quality of the development of the biomedical industry. As the country gradually implements the "Healthy China" strategy, its policy support will become more obvious.
2. Market demand - The biomedical industry has huge market potential. Statistics show that the global market share of China's biomedical industry has increased year by year, with the growth rate of 186.7% from 2014 to 2018, and the rapid growth rate of more than 20% every year from 2015 to 2017. The market size in 2018 reached 228.31 billion yuan, 4.6 times higher than that in 2014. The development prospect in 2018-2022 is very optimistic, and the market size is expected to grow again.
3. Industry competition - In the global scope, the bio pharmaceutical industry is very competitive, and domestic and foreign enterprises are accelerating the establishment of competitive advantages. However, domestic enterprises have certain advantages in cost and technology. If they can better grasp the opportunities and seize the high-end market, they will become the main force for future development.
The biomedical market demand continues to increase, and the pharmaceutical industry is ushering in a golden stage of development. The major scientific and technological project of "new drug discovery" launched by the state has achieved good results. Set off the climax of new drug research and development in China; Accelerated the fundamental transformation of the pharmaceutical industry from imitation to innovation, and most pharmaceutical enterprises began to shift from "focus on sales" to "focus on innovation". Among them, the scale of bio pharmaceutical industry continued to expand.
It is estimated that by 2030, the scale of China's health industry will reach 20 trillion yuan, of which the potential of bio pharmaceutical industry is expected to reach 8 trillion yuan, which is one of the most active and potential industries in China. In recent years, the proportion of the elderly population in China has risen rapidly, and aging has become the basic national condition of China in the future. People's demand for health has increased significantly, and the bio pharmaceutical industry will play a very important role in promoting future economic growth. We are committed to: • Bioindustry industry analysis • Bioindustry park industrial planning, park planning
• Market research on various products of bio industry • Strategic research on bio pharmaceutical and bio energy enterprises
• Strategic research on bio agriculture, bio manufacturing and other enterprises • Investment strategy for diversified bio industry groups
• Bioindustry, biomedicine industry cluster analysis • Bioindustry government research
• Feasibility Study of Bioindustry Segmentation Industry Project • Business Plan of Bioindustry Segmentation Industry Project |
